Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease

Diabetes Care

Volumn 30, Issue 3, 2007, Pages 734-743

  Tolman, Keith G ^a   Fonseca, Vivian ^b   Dalpiaz, Anthony ^c   Tan, Meng H ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH HOSPITAL   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETAINE; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOSARTAN; MEGLITINIDE; METFORMIN; NATEGLINIDE; PEGINTERFERON; PENTOXIFYLLINE; PIOGLITAZONE; REPAGLINIDE; RIBAVIRIN; ROSIGLITAZONE; SULFONYLUREA; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DIABETIC PATIENT; DIAGNOSTIC PROCEDURE; DIET THERAPY; DISEASE ASSOCIATION; DRUG MECHANISM; EXERCISE; HEPATITIS; HEPATITIS C; HUMAN; JAUNDICE; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

BENZAMIDES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; LIVER DISEASES; LIVER FUNCTION TESTS; SAFETY;

EID: 33847629709     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1539     Document Type: Review

References (164)

1. http://diabetes.niddk.nih.gov/dm/pubs/statistics. Accessed 30 July 2005
2. Geiss LS, Herman WH, Smith PJ: Mortality in non-insulin dependent diabetes. In Diabetes in America. 2nd Edition, 1995 p. 233-252 (NIH publ. no. 95-1468)
3. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M: Cause-specific mortality in type 2 diabetes: The Verona Diabetes Study. Diabetes Care 22:756-761, 1999
4. Balkau B, Eschwege E, Ducimetiere P, Richard JL, Warnet JM: The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol 44:465-474, 1991
5. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29:664-669, 1999
6. The U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: OPTN/SRTR annual report: table 9.4a: transplant recipient characteristics, 1995 to 2004: recipients of deceased donor livers [Internet], 2 May 2005. Available from http://www.optn.org/AR2005/ 904a_rec-dgn_li.htm. Ann Arbor, MI. Accessed on 1 September 2006
7. Trombetta M, Spiazzi G, Zoppini G, Muggeo M: Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 22 (Suppl. 2):24-27, 2005
8. Belcher G, Schernthaner G: Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med 22:973-979, 2005
9. Lebovitz HE, Kreider M, Freed MI: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25:815-821, 2002
10. Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH: Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 21:109-113, 1986
11. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21:518-524, 1998
12. Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-438, 1980
13. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74-80, 1990
14. Lee RG: Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 20:594-598, 1989
15. Itoh S, Yougel T, Kawagoe K: Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 82:650-654, 1987
16. Diehl AM, Goodman Z, Ishak KG: Alcohol-like liver disease in nonalcoholics: a clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95:1056-1062, 1988
17. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC: Nonalcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 41:172-179, 1996
18. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, Caro JF: Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 85:1349-1355, 1990
19. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106-1110, 1990
20. Teli MR, James OF, Burt AD, Bennett MK, Day CP: The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology 22:1714-1719, 1995
21. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419, 1999
22. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923, 2003
23. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, Caro JF: Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 85:1349-1355, 1990
24. Cassader M, Gambino R, Musso G, Depetris N, Mecca F, Cavallo-Perin P, Pacini G, Rizzetto M, Pagano G: Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 36:1117-1124, 2001
25. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:450-455, 1999
26. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231, 2002
27. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373-379, 2002
28. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F: Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158-1163, 2001
29. Hui JM, Farrell GC: Clear messages from sonographic shadows?: links between metabolic disorders and liver disease, and what to do about them. J Gastroenterol Hepatol 18:1115-1117, 2003
30. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38:413-419, 2003
31. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48:206-211, 2001
32. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J: Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40:46-54, 2004
33. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F: Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158-1163, 2001
34. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
35. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
36. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
37. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133, 2001
38. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C: Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27:128-133, 1998
39. Esterbauer H, Schaur RJ, Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128, 1991
40. Zatloukal K, Bock G, Rainer I, Denk H, Weber K: High molecular weight components are main constituents of Mallory bodies isolated with a fluorescence activated cell sorter. Lab Invest 64:200-206, 1991
41. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G: The lipid peroxidation end product 4-hydroxy-2,3-nonenal upregulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. Faseb J 11:851-857, 1997
42. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103-1109, 1994
43. Petrides AS: Liver disease and diabetes mellitus. Diabet Rev 2:2-18, 1994
44. Baig NA, Herrine SK, Rubin R: Liver disease and diabetes mellitus. Clin Lab Med 21:193-207, 2001
45. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, Wolk A, McLaughlin JK, Fraumeni JF Jr: Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88:1472-1477, 1996
46. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360-1365, 1997
47. Fujino Y, Mizoue T, Tokui N, Yoshimura T: Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev 17:374-379, 2001
48. El-Serag HB, Tran T, Everhart JE, Kaserer K, Fiedler R, Steindl P, Muller CH, Wrba F, Ferenci P, Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, Negro F, Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, George J, Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460-468, 2004
49. Kazachkov Y, Yoffe B, Khaoustov VI, Solomon H, Klintmalm GB, Tabor E: Microsatellite instability in human hepatocellular carcinoma: relationship to p53 abnormalities. Liver 18:156-161, 1998
50. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR: Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 28:90-97, 1998
51. Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ: Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 329:301-307, 1987
52. Kishimoto Y, Shiota G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, Suou T, Itoh T, Kawasaki H: Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 122:585-589, 1996
53. El-Serag HB, Everhart JE: Diabetes increases the risk of acute hepatic failure. Gastroenterology 122:1822-1828, 2002
54. Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, Everhart JE, Moseley RH, Terrault N, Ackerson L, Selby JV: A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 163:728-734, 2003
55. Gray H, Wreghitt T, Stratton IM, Alexander GJ, Turner RC, O'Rahilly S: High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 12:244-249, 1995
56. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J: High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19:998-1000, 1996
57. Allison ME, Wreghitt T, Palmer CR, Alexander GJ: Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21:1135-1139, 1994
58. Ozyilkan E, Arslan M: Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 91:1480-1481, 1996
59. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP: Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126:586-597, 2004
60. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP: Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328-333, 1999
61. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH: Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 26:30-33, 1998
62. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592-599, 2000
63. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL: Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38:50-56, 2003
64. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296:1655-1657, 2002
65. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M: Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through upregulation of suppressor of cytokine signaling 3. Am J Pathol 165:1499-1508, 2004
66. Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, Negro F: Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 39:119-124, 2001
67. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, George J: Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17:873-881, 2002
68. Di Fiore F, Charbonnier F, Martin C, Frerot S, Olschwang S, Wang Q, Boisson C, Buisine MP, Nilbert M, Lindblom A, Frebourg T: Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. J Med Genet 41:18-20, 2004
69. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE: Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 24:1349-1357, 2006
70. Sabile A, Perlemuter G, Bono F, Kohara K, Demaugre F, Kohara M, Matsuura Y, Miyamura T, Brechot C, Barba G: Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 30:1064-1076, 1999
71. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122:366-375, 2002
72. Tanaka H, Shiota G, Kawasaki H: Changes in glucose tolerance after interferon-alpha therapy in patients with chronic hepatitis C. J Med 28:335-346, 1997
73. Konrad T, Zeuzem S, Vicini P, Toffolo G, Briem D, Lormann J, Herrmann G, Berger A, Kusterer K, Teuber G, Cobelli C, Usadel KH: Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 30:111-121, 2000
74. Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D: Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 53:420-424, 2004
75. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C: Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 18:549-558, 2003
76. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS: One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100:1072-1081, 2005
77. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, Okada T, Angulo P: Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 43:1060-1066, 2005
78. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603-608, 2005
79. Douketis JD, Feightner JW, Attia J, Feldman WF: Periodic health examination, 1999 update. I. Detection, prevention and treatment of obesity: Canadian Task Force on Preventive Health Care. Cmaj 160:513-525, 1999
80. Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L, Foess-Wood L, Sherbondy MA, Conjeevaram HS: Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 101:2247-2253, 2006
81. Solga S, Alkhuraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, Magnuson T: Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 49:1578-1583, 2004
82. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D: Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292:1440-1446, 2004
83. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37:909-916, 2003
84. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G: Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19:616-627, 1994
85. Marks V, Teale JD: Drug-induced hypoglycemia. Endocrinol Metab Clin North Am 28:555-577, 1999
86. Burge MR, Zeise TM, Sobhy TA, Rassam AG, Schade DS: Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care 22:2037-2043, 1999
87. Zimmerman HJ: Drug-induced liver disease. In Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, Lippincott Williams and Williams, 1991, p. 430
88. Nair S, Diehl AM, Wiseman M, Farr GH, Jr., Perrillo RP: Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20:23-28, 2004
89. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N: Metformin in non-alcoholic steatohepatitis. Lancet 358:893-894, 2001
90. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19:537-544, 2004
91. Nair S, Diehl AM, Perille R: Metformin in non-alchoholic steatohepatitis: efficacy and safety: a preliminary report (Abstract). Gastroenterology 122 (Suppl. 2) 2002
92. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA: Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364-1370, 2003
93. Freedman R, Uwaifo G, Lutchman G, Kittichaipromrat., Park Y, Kleiner D, Yanovski J, Hoofnagle J: Changes in insulin sensitivity and improvements in liver histology in patients with nonalcoholic steatohepatitis (NASH) treated with pioglitazone (PIO) (Abstract). Diabetes 52 (Suppl. 1):A76, 2003
94. Harrison S, Belfort R, Brown K, Darland C, Finch J, Fincke C, Havranek R, Hardies J, Dwivedi S, Berria R, Tio F, Schenker S, Cusi K: A double-blind, placebo-controlled trial of pioglitazone in the treatment of non-alcoholic steatohepatitis (NASH) (Abstract). Gastroenterology 128 (Suppl 2):A681, 2005
95. Acosta R, Molina E, O'Brien C, Cobo M, Amaro R, Neff G, Schiff E: The use of pioglitazone in non-alcoholic steatohepatitis (Abstract). Gastroenterology 120 (Suppl. 1):A-546, 2001
96. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196, 2004
97. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR: Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 38:434-440, 2003
98. Frier BM, Stewart WK: Cholestatic jaundice following chlorpropamide self-poisoning. Clin Toxicol 11:13-17, 1977
99. Gupta R, Sachar DB: Chlorpropamide-induced cholestatic jaundice and pseudomembranous colitis. Am J Gastroenterol 80:381-383, 1985
100. Reichel J, Goldberg S, Ellenberg M, Schaffner F: Intrahepatic cholestasis following administration of chlorpropamide: report of a case with electron microscope observations. Am J Med 28:654, 1960
101. Choudhury S, Hirschberg Y, Filipek R, Lasseter K, McLeod JF: Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmacol 40:634-640, 2000
102. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-579, 1996
103. Gentile S, Turco S, Guarino G, Oliviero B, Annunziata S, Cozzolino D, Sasso FC, Turco A, Salvatore T, Torella R: Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab 3:33-40, 2001
104. Gentile S, Guarino G, Romano M, Alagia IA, Fierro M, Annunziata S, Magliano PL, Gravina AG, Torella R: A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 3:184-191, 2005
105. Andrade RJ, Lucena MI, Rodriguez-Mendizabal M: Hepatic injury caused by acarbose. Ann Intern Med 124:931, 1996
106. Carrascosa M, Pascual F, Aresti S: Acarbose-induced acute severe hepatotoxicity (Letter). Lancet 349:698, 1998
107. Diaz-Gutierrez FL, Ladero JM, Diaz-Rubio M: Acarbose-induced acute hepatitis. Am J Gastroenterol 93:481, 1998
108. Zawadski J, Green L, Graham B: Troglitazone-associated 15-month post-marketing hepatotoxicity: FDA science forum [article online]. Available from http://www.cfsan.fda.gov~frf/forum02/a187ab4.htm. Accessed 5 February 5 2002
109. Tolman KG, Fonseca V, Tan MH, Dalpiaz A: Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 141:946-956, 2004
110. Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B: Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 47:1632-1637, 2002
111. Al-Jalman J, Arjomand H, Kemp DG, Mittal M: Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med 132:121-124, 2000
112. Forman LM, Simmons DA, Diamond RH: Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 132:118-121, 2000
113. Gouda HE, Khan A, Schwartz J, Cohen RI: Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med 111:584-585, 2001
114. Chase MP, Yarze JC: Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 97:502-503, 2002
115. Maeda K: Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 135:306, 2001
116. May LD, Lefkowitch JH, Kram MT, Rubin DE: Mixed hepatocellular- cholestatic liver injury after pioglitazone therapy. Ann Intern Med 136:449-452, 2002
117. Andersen T, Gluud C, Franzmann MB, Christoffersen P: Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12:224-229, 1991
118. Drenick EJ, Simmons F, Murphy JF: Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 282:829-834, 1970
119. Tolman KG: The liver and lovastatin. Am J Cardiol 89:1374-1380, 2002
120. Horlander J, Kwo P, Cummings O: Atorvastatin for the treatment of NASH (Abstract). Gastroenterology 5:A-544, 2001
121. Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F: Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 17:713-718, 2003
122. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126:1287-1292, 2004
123. Putterman C, Livshitz T: Captopril-induced liver dysfunction. Harefuah 121:92-93, 1991 [article in Hebrew]
124. Shionoiri H, Nomura S, Oda H,: Hepatitis associated with captopril and enalapril but not with delapril in a patient with congestive heart failure receiving chronic hemodialysis. Curr Ther Res 42:1171-1176, 1986
125. Rosellini SR, Costa PL, Gaudio M, Saragoni A, Miglio F: Hepatic injury related to enalapril (Letter). Gastroenterology 97:810, 1989
126. Larrey D, Babany G, Bernuau J, Andrieux J, Degott C, Pessayre D, Benhamou JP: Fulminant hepatitis after lisinopril administration. Gastroenterology 99:1832-1833, 1990
127. Tabak F, Mert A, Ozaras R, Biyikli M, Ozturk R, Ozbay G, Senturk H, Aktuglu Y: Losartan-induced hepatic injury. J Clin Gastroenterol 34:585-586, 2002
128. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40:1222-1225, 2004
129. Lavine JE, Schwimmer JB: Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 8:549-558, viii-ix, 2004
130. Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356-1362, 1999
131. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD: Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 43:26-31, 1991
132. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745-750, 2002
133. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Croce LS, Grigolato P, Paoletti S, de Bernard B, et al.: Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 5:281-285, 1995
134. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100, 2001
135. Goessling W, Friedman LS: Increased liver chemistry in an asymptomatic patient. Clin Gastroenterol Hepatol 3:852-858, 2005
136. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ: Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22:222-226, 1998
137. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99:1408-1413, 1990
138. Eriksson S, Eriksson KF, Bondesson L: Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 220:83-88, 1986
139. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27:103-107, 1997
140. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53:413-419, 2004
141. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE: Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39:1647-1654, 2004
142. Rozental P, Biava C, Spencer H, Zimmerman HJ: Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 12:198-208, 1967
143. Comar KM, Sterling RK: Review article: Drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 23:207-215, 2006
144. Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH: Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 13:1180-1186, 2005
145. Basaranoglu M, Acbay O, Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis (Letter). J Hepatol 31:384, 1999
146. Lavine JE: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136:734-738, 2000
147. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96:2711-2717, 2001
148. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P: A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 20:623-628, 2004
149. Adams LA, Zein CO, Angulo P, Lindor KD: A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 99:2365-2368, 2004
150. Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA, Liang TJ, Hoofnagle JH: Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 4:1048-1052, 2006
151. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176, 2004
152. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008-1017, 2003
153. Ratziu V, Charlotte F, Jacqueminet S, Podevin P, Serfaty L, Bruckert E, Grimaldi A, Poynard T: A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis: results of the FLIRT pilot trial (Abstract). Hepatology 44 (Suppl. 1):201A, 2006
154. Holoman J, Glasa J, Kasar J et al: Serum markers of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH): correlation to liver morphology and effect of therapy (Abstract). J Hepatol 32 (Suppl. 2):210, 2000
155. Lindor K: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized, placebo-controlled study (Abstract). Gastroenterology 124 (Suppl.1):A336, 2003
156. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A: Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15:1667-1672, 2001
157. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98:2485-2490, 2003
158. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS: A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2:1107-1115, 2004
159. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:37-46, 2005
160. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171, 2004
161. Koivisto VA, Pelkonen R, Cantell K: Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 38:641-647, 1989
162. Imano E, Kanda T, Ishigami Y, Kubota M, Ikeda M, Matsuhisa M, Kawamori R, Yamasaki Y: Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 28:189-193, 1998
163. Ishigami Y, Kanda T, Wada M, Shimizu Y: Glucose intolerance during interferon therapy in patients with chronic hepatitis type C. Nippon Rinsho 52:1901-1904, 1994 [article in Japanese]
164. Ito Y, Takeda N, Ishimori M, Akai A, Miura K, Yasuda K: Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C. J Hepatol 31:215-220, 1999